MedTrace Logo

The Role of Intestinal Inflammation in Irritable Bowel Syndrome (IBS)

NCT01072903 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 78

Last updated 2013-12-12

No results posted yet for this study

Summary

The research project addresses the following hypotheses (A) the normal balance of beneficial and detrimental commensal intestinal bacteria is deranged in IBS, with selective alterations in clinically defined patient subsets i.e., diarrhea predominant IBS (D-IBS) and post-infectious IBS (PI-IBS); (B) these changes in intestinal microflora are associated with sub-clinical mucosal inflammation and activation of the mucosal immune system; and (C) activation of the mucosal immune system leads to alterations in gastrointestinal (GI) functions (i.e., motility and sensation) and functional symptoms.

Conditions

  • Inflammation
  • Colon, Irritable
  • Colonic Diseases, Functional
  • Irritable Bowel Syndrome

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Yehuda Ringel, MD · UNC Chapel Hill Department of Gastroenterology and Hepatology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01072903 on ClinicalTrials.gov